Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
BTN2A3P (Butyrophilin subfamily 2 member A3, pseudogene) is a non-protein-coding member of the butyrophilin gene family, localized to chromosome 6 within the human major histocompatibility complex (MHC). Unlike its functional paralogs, BTN2A3P is a pseudogene, so it does not encode a full-length functional protein[2][5]. The butyrophilin gene family is involved with immune modulation and regulation of T cell activity, but BTN2A3P’s precise biological relevance remains undetermined. Some associations link its expression to immune-related tissues and suggest possible involvement in immune response regulation, yet there is no experimental confirmation of a functional protein product or validated disease role. BTN2A3P is not considered a receptor, enzyme, or actionable drug target, and it has no established applications as a biomarker for patient selection or efficacy monitoring[3][5]. Summary: BTN2A3P is a pseudogene—commonly misinterpreted as a protein-coding immune receptor—without evidence for direct biological activity, drug interactions, or therapeutic relevance[2][3][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Butyrophilin subfamily 2 member A3, pseudogene (BTN2A3P).